Comparative Pharmacology
Head-to-head clinical analysis: HUMATIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMATIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
HUMATIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
None Documented
None Documented
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic